1. 免疫チェックポイント阻害剤を使用した際の肝機能障害の特徴
   , 2020, Kanzo CrossRef
2. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
   Pierpaolo Correale et al, 2020, Cells CrossRef
3. Classical Examples of the Concept of the ASIA Syndrome
   Vânia Borba et al, 2020, Biomolecules CrossRef
4. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
   Pei Yi Lee et al, 2021, Cancers CrossRef
5. Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
   Atsuto Mouri et al, 2021, Front. Oncol. CrossRef
6. Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune–Biological Evaluation and Case Report
   Cirino Botta et al, 2021, IJMS CrossRef
7. Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
   Valerio Nardone et al, 2021, Front. Oncol. CrossRef
8. Circulating predictive markers of immune checkpoint inhibitors in non-small cell lung cancer
   A. A. Musaelyan et al, 2021, Usp. mol. onkol CrossRef
9. Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis.
   Michele Caraglia, 0 CrossRef
10. Real-World Effectiveness of Immunotherapies in Pre-Treated, Advanced Non-Small Cell Lung Cancer Patients: A Systematic Literature Review
    Ariadna Juarez-Garcia et al, 2022, Lung Cancer CrossRef
11. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
    Hui Tang et al, 2022, Front. Immunol. CrossRef
12. Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study
    Iñigo Les et al, 2022, Front. Pharmacol. CrossRef
13. The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
    Qianning Zhang et al, 2022, Front. Oncol. CrossRef
14. Antibody Diversity in Cancer: Translational Implications and Beyond
    Raghuram Reddy et al, 2022, Vaccines CrossRef
15. PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach
    Antonella Fameli et al, 2022, Front. Oncol. CrossRef
16. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
    Leticia Alserawan et al, 2022, IJMS CrossRef
17. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
    A Daban et al, 2023, OncoImmunology CrossRef
18. Role of B cells in immune‐related adverse events following checkpoint blockade
    Kavita M. Dhodapkar et al, 2023, Immunological Reviews CrossRef
19. The presence of autoantibodies is associated with improved overall survival in lung cancer patients
    Keying Jing et al, 2023, Front. Oncol. CrossRef
20. B cell clonality in cancer
    E.A. Bryushkova et al, 2024, Seminars in Immunology CrossRef
21. Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort
    Fulvia Ceccarelli et al, 2024, Clin Exp Med CrossRef